Published 3 days ago • loading... • Updated 3 days ago

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

HBM Alpha Therapeutics has announced a collaboration and license agreement to advance therapies targeting corticotropin-releasing hormone for various disorders.
The partner gains exclusive global rights, except in Greater China, to develop and commercialize HAT001, a neutralizing antibody for CRH.
HBM Alpha Therapeutics is eligible to receive up to $395 million, including milestone payments and tiered royalties on future product sales.
Dr. Jingsong Wang stated that this collaboration represents a pivotal step for HBM Alpha Therapeutics in delivering innovative solutions for patients facing challenging endocrine disorders.

Insights by Ground AI

Does this summary seem wrong?

31 Articles

All

Left

Center

Right

thepilotnews.com

+29 Reposted by 29 other sources

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance…

3 days ago·Plymouth, United States

Read Full Article

pipelinereview

HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies - Pipelinereview

CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SHANGHAI, China I February 25, 2025 I HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders. Under the agreement, the partner gains exclusive global rights,…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year